title: Clinical significance and biological roles of TRIM24 in human bladder carcinoma.
abstract: Tripartite motif-containing 24 (TRIM24), also known as transcription intermediary factor 1-alpha (TIF1α), is a chromatin-associated protein which as been has been implicated in carcinogenesis. However, its expression profile and biological roles in human bladder carcinoma has not been investigated. In this study, we examined its expression in 95 bladder cancer specimens. We found that TRIM24 expression was upregulated in 39 of 95 (41.1 %) specimens compared with normal control. TRIM24 overexpression was associated with local invasion and advanced grade of bladder cancer. In addition, we transfected TRIM24 plasmid into BIU-87 cell line and TRIM24 siRNA into 5637 cell line. Colony formation, CCK-8, and transwell assay were used to assess its biological roles in bladder cancer cells. The result showed that TRIM24 could facilitate cancer cell growth and invading ability. Western blot analysis demonstrated that TRIM24 upregulated cyclin D1, cyclin E, p-IκBα, and p-AKT expression, suggesting TRIM24 activates NF-κB and AKT pathways. In addition, NF-κB inhibitor reversed the effect of TRIM24 on cyclin D1. In conclusion, TRIM24 is overexpressed in human bladder cancer and facilitates bladder cancer growth and invasion, possibly through NF-κB and AKT signaling pathways.
authors.affiliation: Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Dongwei
authors.initials: D
authors.lastname: Xue
authors.affiliation: Department of Pathology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Xiuwei
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Xilin
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Li
authors.affiliation: Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Chunlai
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Yili
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China. wangpingcmu@126.com.
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
mesh_terms: D000368:Aged; D017209:Apoptosis / Q000235:genetics; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology; D002352:Carrier Proteins / Q000096:biosynthesis* / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000235:genetics; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009367:Neoplasm Staging; D051058:Oncogene Protein v-akt / Q000235:genetics; D015398:Signal Transduction; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: D002352:Carrier Proteins; D016328:NF-kappa B; D009363:Neoplasm Proteins; C555317:TRIM24 protein, human; D051058:Oncogene Protein v-akt
keywords: AKT; Bladder cancer; NF-κB; Proliferation; TRIM24
references.citation: Tumour Biol. 2012 Dec;33(6):2007-17
references.pmid: 23136087
references.citation: Am J Pathol. 2011 Apr;178(4):1461-9
references.pmid: 21435435
references.citation: Nat Genet. 2007 Dec;39(12 ):1500-6
references.pmid: 18026104
references.citation: Biochem Soc Trans. 1997 May;25(2):605-12
references.pmid: 9191165
references.citation: Tumour Biol. 2014 May;35(5):4131-6
references.pmid: 24443255
references.citation: Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
references.pmid: 16341064
references.citation: Biochem Soc Trans. 2010 Feb;38(Pt 1):217-22
references.pmid: 20074063
references.citation: Tumour Biol. 2013 Aug;34(4):2099-108
references.pmid: 23055195
references.citation: Tumour Biol. 2013 Oct;34(5):2835-42
references.pmid: 23681803
references.citation: PLoS One. 2014 Jan 07;9(1):e85462
references.pmid: 24409330
references.citation: Nature. 2010 Dec 16;468(7326):927-32
references.pmid: 21164480
references.citation: PLoS One. 2013 May 22;8(5):e63887
references.pmid: 23717505
references.citation: Oncogene. 2015 Jan 29;34(5):600-10
references.pmid: 24469053
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: EMBO J. 1995 May 1;14(9):2020-33
references.pmid: 7744009
references.citation: Am J Pathol. 2013 Feb;182(2):339-49
references.pmid: 23201130
references.citation: Cancer Sci. 2007 May;98(5):629-35
references.pmid: 17359287
references.citation: Tumour Biol. 2012 Apr;33(2):307-14
references.pmid: 22095135
references.citation: PLoS One. 2012;7(5):e37657
references.pmid: 22666376
references.citation: EMBO J. 1996 Dec 2;15(23):6701-15
references.pmid: 8978696
references.citation: Tumour Biol. 2014 Mar;35(3):2075-80
references.pmid: 24092575